# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹920 Cr** Q4 (+19.1%) · **₹3,420 Cr** FY26 (+13.8%) * **Adjusted EBITDA:** **₹200 Cr** Q4 (+64%) · **₹702 Cr** FY26 (+59.6%) * **EBITDA Margin:** 21.7% Q4 · 20.5% FY26 (+590 bps) * **Gross Margin:** 55.1% Q4 (+236 bps) · 54.3% FY26 (+321 bps) * **PAT:** **₹66 Cr** Q4 (vs. loss) · **₹225 Cr** FY26 (+1,324%) ## B. Revenue Growth & Mix * **Formulations Outperformance:** Top-line growth was primarily anchored by robust double-digit momentum in formulations, which outpaced the mid-single-digit growth seen in the API segment. * **Segment Contribution:** Formulations now represent the largest revenue share at **INR 1,866 Cr** for the full year, compared to **INR 1,491 Cr** for APIs. ## C. Margins & Profitability * **Record Earnings Power:** The company delivered its strongest quarterly EBITDA in history, successfully surpassing the **20% guided margin** threshold ahead of the original FY28 schedule. * **Bottom-Line Turnaround:** Massive year-on-year PAT expansion reflects a successful rebound from previous losses, though **20%** of PAT remains attributable to minority interests. * **Efficiency Initiatives:** Management is focused on converting EBITDA to net profit by transitioning subsidiaries to a **25%** tax regime (down from **35%**) and optimizing finance costs. * **Amortization Tailwinds:** Annual goodwill amortization is projected to collapse from **INR 100 Cr** to **INR 35 Cr**, effectively offsetting depreciation from new CAPEX and stabilizing the total depreciation run rate. * **Forward Guidance:** Despite upcoming pre-operative expenses for capacity expansion and R&D, leadership expresses confidence in maintaining current margin levels through FY27-28. ## D. Balance Sheet & Liquidity * **Credit Strengthening:** Significant deleveraging and disciplined capital management resulted in a credit rating upgrade to **AA-** (Long-term) and **A1+** (Short-term). * **Working Capital Dynamics:** A slight **5 to 6 day** increase in the Q4 collection cycle was driven by rapid scaling and specific market exposure in Turkey; management views the risk as controlled. * **Capital Allocation:** Strong free cash flow and a deleveraged balance sheet have positioned the firm to evaluate selective inorganic acquisitions alongside organic growth. --- # 2. Segment & Product Performance ## A. Key Figures * **Animal Health Revenue:** **₹400 Cr** FY26 Run Rate (vs. ₹350 Cr historical) * **Human Health Revenue:** **₹400–425 Cr** U.S. Formulations · **₹550 Cr** Spain Business * **CDMO Revenue:** **₹200 Cr** Current (~15% of API Top Line) · **₹60 Cr** Annualized Rate * **API Growth:** **7%–8%** Current Year * **Target Margins:** **30%–35%** Gross Margin on commodity products (being phased out) ## B. Animal Health Growth * **Strategic Inflection Point:** The segment broke a five-year stagnation, achieving a higher run rate through manufacturing execution and R&D acceleration. * **Innovator Focus:** Management is pivoting toward the innovator segment (70-80% market share), forecasting **30% to 40%** growth next year. * **Geographic Expansion:** Near-term growth of approximately **INR 100 Cr** is expected from entering China and Europe with existing products. * **Pipeline Longevity:** R&D is targeting patent expirations through **2035**, with new patent-expiry revenue expected to materialize in **FY28 or FY29**. ## C. Human Health Formulations * **Portfolio Premiumization:** Exceptional FY26 performance driven by a shift toward complex products and the internalization of API production for the Indian market. * **Regional Strength:** Robust revenue contributions from Spain and the U.S. underpin the formulation business's scale. ## D. API Portfolio Optimization * **Margin Enhancement Strategy:** Deliberate reduction in low-margin commodity intermediate sales to favor high-value, complex, and high-potent APIs. * **Customer Lock-in:** Transition to specialized areas has resulted in validated products and secured customer approvals, expected to drive growth from FY26 onwards. * **Input Cost Resilience:** Minimal impact from raw material volatility due to a presence in regulated markets with sustainable pricing and cost pass-through capabilities. * **Future Pipeline:** Identified **15 to 20** new API products for patents expiring 2028–2035, including **5 to 6** large-scale opportunities. ## E. CDMO Business Contribution * **Scaling Projections:** Management expects to more than double the current annualized revenue rate to **INR 125–150 Cr** within the next **12 to 18 months**. * **Structural Evolution:** While current margins are stable, significant expansion is contingent on a long-term shift (5-6 years) toward a higher CDMO mix. * **Service Model:** Growth is anchored in Phase III NCE molecules and life cycle management for global innovators and specialty firms. --- # 3. Manufacturing & Capacity ## A. Global Facility Expansion & Infrastructure * **Strategic Footprint Expansion:** Manufacturing capacity is being scaled via new expansion in **Spain** and debottlenecking initiatives in **Turkey** to underpin future volume requirements. * **Specialized Oncology Capabilities:** A dedicated potent lab has been established within R&D, with a new oncology lab slated for completion within the **next two quarters** to drive finished product development. * **Flexible Production Scale:** Facilities offer versatile manufacturing ranges from **0.5 kg to 100 kg batches**, supported by a specialized R&D team to handle varying client requirements. ## B. Vertical Integration & CDMO Strategy * **Value Chain Optimization:** Margins are being protected through aggressive forward integration into APIs/formulations and backward integration to secure the internal supply chain. * **High-Potency Partnership Model:** The company is leveraging **two dedicated high-potent facilities** to partner with formulation players on complex APIs while utilizing internal setups for standard products. * **CDMO Evolution:** Infrastructure is being built to transition from lifecycle management toward **Phase III and commercial-stage CDMO work**, a strategic shift expected to mature over the next **two years**. ## C. R&D Investment & Talent * **Human Capital Strength:** The R&D engine is powered by **250 API scientists** and **55 to 60 human health formulation scientists**, providing sufficient technical depth for current operations. * **Animal Health Pivot:** Management is aggressively reallocating CapEx and talent toward animal health formulations, aiming to scale R&D output by **5x to 6x** within the next **6 months**. * **Product Pipeline Acceleration:** R&D expansion in the companion animal sector is targeted to deliver a steady-state output of **7 to 8 new products per year**. * **Complex Molecule Focus:** Future R&D spend is prioritized toward **complex molecules** in both human and animal health, balancing long-term margin profiles against immediate growth. --- # 4. M&A & Strategic Integration ## A. Key Figures * **Current Annualized Synergies:** **₹50 Cr** to **₹60 Cr** * **Targeted Synergy Outlook:** **₹125 Cr** to **₹150 Cr** next 12–18 months * **B. S. Subsidiary Revenue:** ~**₹425 Cr** * **Subsidiary Ownership:** **60%** stake in U.S. (Appco) and Spain units · **40%** minority interest ## B. Merger Synergy Realization * **Accelerated Integration:** FY26 served as a transformative year, unifying operations into a single platform and achieving internal FY27 run-rate targets ahead of schedule. * **Upward Synergy Revision:** Management significantly raised its synergy targets based on better-than-anticipated operational performance and upcoming **capacity approvals** at Viyash. * **Operating Leverage:** Successful consolidation of corporate functions has enhanced execution capabilities and positioned the team for robust growth entering FY27. ## C. Subsidiary Ownership & Inorganic Strategy * **Minority Buyouts:** Plans are underway to acquire the remaining **40%** stakes in U.S. and Spanish subsidiaries over the next **1 to 2 years** (extending to **2028** for Spain). * **Selective M&A:** Open to inorganic growth to bolster CDMO capabilities, prioritizing high-quality assets over purely financial scale. * **Geographic Expansion:** Front-end strategy for companion animals is targeting **Europe and India**, alongside existing footprints in **Turkey and Brazil**. ## D. Partnership Model Evolution * **CDMO Pivot:** The formulation business now operates as a full CDMO model, partnering with majors like **Cipla and Dr. Reddy's** under **50/50 profit-sharing** agreements. * **Complex Product Pipeline:** Developed over **16 complex products** with launches projected between **2029 and 2037** under a specialty filing model. * **Joint Development Framework:** Initiated a new model with formulation players to handle API development; **one product** is complete with **3 to 4 additional products** currently in the pipeline. --- # 5. Market & Geography Mix ## A. Key Figures * **European Pet Insurance Coverage:** **15% to 25%** * **B. S. Pet Population:** **9.4 Crore** dogs · **9.2 Crore** cats * **European Companion Animal TAM:** **$1 Billion** (excluding vaccines) ## B. European Market Expansion * **Infrastructure Scaling:** Strengthening front-end teams and leveraging EU GMP-approved sites in **Turkey** and **Spain** to facilitate entry into all European markets. * **Generic Conversion Drivers:** Low insurance penetration coupled with rising pet ownership is accelerating the shift toward affordable generic formulations. * **Large Animal Strategy:** Expanding the large animal segment specifically through injectable and powder solution capabilities. ## C. U.S. Formulation Strategy * **Phased Entry:** The U.S. is designated as a next-phase priority, with management considering **inorganic opportunities** to navigate complex regulatory and BA/BE study requirements. * **Competitive Positioning:** Combating market commoditization through internal API sourcing and a focus on proprietary Intellectual Property (IP) for generic molecules. * **Market Shift:** Capitalizing on a growing U.S. consumer trend toward generic and affordable drugs for companion animals. ## D. Emerging Market Presence * **Global Footprint:** Pursuing large animal product growth in **Latin America** via a Brazil-based site, with imminent front-end expansion into **Mexico, Vietnam, and Africa**. * **Resilience in Volatile Regions:** Maintaining strong volume growth and a positive pipeline outlook despite hyperinflationary pressures in markets like **Turkey**. ## E. Companion Animal Opportunity * **Strategic Growth Pillar:** Identified as the primary driver for the next **5 to 6 years**, supported by a distribution partnership with **Boehringer Ingelheim (BI)**. * **Pipeline Focus:** R&D is targeting differentiated products for cats and dogs, specifically focusing on molecules coming off-patent by **2029 or 2030**. * **Domestic Potential:** Targeting the Indian companion animal market, currently valued at a **few hundred crores**, as part of a broader rapid genericization strategy. --- # 6. Risks & Regulatory Factors ## A. Key Figures * **Inventory Buffer:** **1–2 Quarters** of key raw materials secured * **Geopolitical Impact:** **₹1 Cr – ₹2 Cr** in Q4 (freight and solvent costs) * **Animal Health Pricing:** **60% – 70%** of innovator price (vs. 10–15% in human generics) ## B. Geopolitical & Supply Chain * **Supply Chain Resilience:** Strategic inventory positioning mitigates immediate risks from raw material volatility and geopolitical disruptions. * **Cost Mitigation:** Management is countering rising input and logistics costs through targeted price increases and operational efficiencies, specifically **solvent recovery** initiatives. ## C. Compliance & Approval Risks * **Regulatory Tailwinds:** Current growth is underpinned by approvals secured over the last **18 to 24 months** for the converted API and finished product portfolio. * **Innovation Pipeline:** Collaboration with **8 to 10 major innovators** is nearing a catalyst phase, with global approvals for long-term projects expected by year-end. * **Client Confidence:** Enhanced quality systems and R&D efficiency over the last **6 to 9 months** have strengthened relationships with the existing client base, paving the way for upcoming product launches. ## D. Pricing & Competition * **Sector-Specific Pricing Power:** The animal health segment offers superior margin protection compared to human medicine, maintaining significantly higher price points relative to innovators. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth (Life Cycle Mgmt):** **40%** FY27 Target * **Revenue Base (Life Cycle Mgmt):** **₹200 Cr - ₹225 Cr** Current * **Long-term Growth Rate:** **15%** Sustainable 5-year CAGR * **EBITDA Target:** **₹1,000 Cr** 2-3 Year Horizon (vs. **₹700 Cr** current) * **Gross Margin Stability:** **+/- 1% to 2%** Variance over 3-5 years ## B. FY27 Growth Targets * **Strategic Roadmap:** Management maintains a positive outlook for the first full year of the combined entity, supported by a robust product pipeline and merger synergies. * **Segment Momentum:** Significant double-digit expansion expected in the innovative business life cycle management segment as products transition to commercialization. * **Financial Priorities:** Core focus remains on debt reduction, efficient capital allocation, and maximizing cash flow to support the transition to a higher EBITDA tier. ## C. Long-term Margin & Sector Outlook * **Margin Sustainability:** Gross margin profile is expected to remain stable, with management viewing current levels as reasonable for the existing business mix. * **Multi-Sector Levers:** Long-term growth targets are underpinned by diversified contributions across the Formulations, API, and CDMO sectors. ## D. Strategic Platform Building * **Companion Animal Expansion:** FY27 is designated as a foundational year for the animal health segment, requiring dedicated Capex for **R&D expansion** and **new manufacturing infrastructure**. * **Upcoming Guidance:** Formal confirmation of the timeline for the four-digit EBITDA target is slated for the **June investor meeting**.